Other markers of aggressive PitNET disease have been investigated, including in the following domains: (i) genetics, with germline mutations in AIP and MEN1 genes, or duplications in GPR101, as well as somatic mutations in genes ATRX or TP53, leading to more invasive and resistant PitNETs [45,46,47,48,49,50]; (ii) transcriptional and post-transcriptional regulation [51,52,53,54]; (iii) serum inflammation-based biomarkers [55,56,57]; and (iv) tumour microenvironment [58,59,60]. This evidence concerns the gene TP53 and neoplasm.